Citalopram

• 

  Subject Areas on Research

  • A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. 
  • A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. 
  • A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. 
  • A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. 
  • Acceptability of second-step treatments to depressed outpatients: a STAR*D report. 
  • Acute 5-HT reuptake blockade potentiates human amygdala reactivity. 
  • Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. 
  • Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. 
  • An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. 
  • An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. 
  • Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. 
  • Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. 
  • Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study. 
  • Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. 
  • Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. 
  • Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. 
  • Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. 
  • Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. 
  • Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. 
  • Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). 
  • Bupropion in the treatment of outpatients with asthma and major depressive disorder. 
  • CYP2C19 variation and citalopram response. 
  • Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. 
  • Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. 
  • Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study. 
  • Citalopram and quality of life in lung transplant recipients. 
  • Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. 
  • Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. 
  • Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial. 
  • Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. 
  • Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. 
  • Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. 
  • Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. 
  • Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. 
  • Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. 
  • Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D. 
  • Depression treatment in patients with general medical conditions: results from the CO-MED trial. 
  • Depression, IV: STAR*D treatment trial for depression. 
  • Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. 
  • Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. 
  • Diurnal mood variation in outpatients with major depressive disorder. 
  • Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. 
  • Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. 
  • Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. 
  • Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. 
  • Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. 
  • Effect of age at onset on the course of major depressive disorder. 
  • Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. 
  • Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. 
  • Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. 
  • Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. 
  • Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. 
  • Escitalopram in specific phobia: results of a placebo-controlled pilot trial. 
  • Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. 
  • Escitalopram related edema in a patient with Hashimoto's thyroiditis. 
  • Escitalopram treatment of trichotillomania. 
  • Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. 
  • Ethnicity/race and outcome in the treatment of depression: results from STAR*D. 
  • Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. 
  • Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. 
  • Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. 
  • Family history of depression and therapeutic outcome: findings from STAR*D. 
  • Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. 
  • Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. 
  • Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. 
  • Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. 
  • High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. 
  • Income and attrition in the treatment of depression: a STAR*D report. 
  • Increase in work productivity of depressed individuals with improvement in depressive symptom severity. 
  • Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression. 
  • Inflammation-Induced Histamine Impairs the Capacity of Escitalopram to Increase Hippocampal Extracellular Serotonin. 
  • Insured and non-insured depressed outpatients: how do they compare? 
  • International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. 
  • Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. 
  • Limitations in efficacy of antidepressant monotherapy. 
  • Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial. 
  • MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression. 
  • Medication augmentation after the failure of SSRIs for depression. 
  • Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. 
  • Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. 
  • Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. 
  • Motor cortex excitability after vagus nerve stimulation in major depression. 
  • Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. 
  • Naturalistic study of the early psychiatric use of citalopram in the United States. 
  • Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. 
  • Pain in depression: STAR*D study findings. 
  • Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. 
  • Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. 
  • Pharmacogenetics studies in STAR*D: strengths, limitations, and results. 
  • Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication. 
  • Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. 
  • Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. 
  • Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. 
  • Prediction of nonremission to antidepressant therapy using diffusion tensor imaging. 
  • Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. 
  • Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. 
  • Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. 
  • Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. 
  • Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. 
  • Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. 
  • Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. 
  • Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. 
  • Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial. 
  • Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray? 
  • SLC6A4 variation and citalopram response. 
  • Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. 
  • Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. 
  • Selective serotonin reuptake inhibitors for fibromyalgia syndrome. 
  • Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. 
  • Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study. 
  • Sex differences in response to citalopram: a STAR*D report. 
  • Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. 
  • Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. 
  • TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. 
  • The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. 
  • The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. 
  • The Quick Inventory of Depressive Symptomatology-Self-report: a psychometric evaluation in patients with asthma and major depressive disorder. 
  • The STAR*D study: treating depression in the real world. 
  • The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. 
  • The impact of nonclinical factors on care use for patients with depression: a STAR*D report. 
  • The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. 
  • The selective serotonin reuptake inhibitor citalopram induces the storage of serotonin in catecholaminergic terminals. 
  • Therapy for mental stress-induced myocardial ischemia--reply. 
  • Toward a Definition of "No Meaningful Benefit" From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales. 
  • Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial. 
  • Treatment of social anxiety disorder with citalopram. 
  • Treatment outcome variation between depression symptom combinations in the STAR*D study. 
  • Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. 
  • Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial). 
  • Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. 
  • What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. 
  • What predicts attrition in second step medication treatments for depression?: a STAR*D Report. 
  • [A new quality of the therapy of anxiety and depression--escitalopram]. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology